Chaput Nathalie, Flament Caroline, Viaud Sophie, Taieb Julien, Roux Stephan, Spatz Alain, André Fabrice, LePecq Jean-Bernard, Boussac Muriel, Garin Jérôme, Amigorena Sebastian, Théry Clotilde, Zitvogel Laurence
ERM0208 Institut National de la Santé Et de la Recherche Médicale, Faculté de Médecine Paris Sud-Université, Paris XI, France.
J Leukoc Biol. 2006 Sep;80(3):471-8. doi: 10.1189/jlb.0206094. Epub 2006 Jun 29.
Exosomes are nanometer-sized membrane vesicles invaginating from multivesicular bodies and secreted from different cell types. They represent an "in vitro" discovery, but vesicles with the hallmarks of exosomes are present in vivo in germinal centers and biological fluids. Their protein and lipid composition is unique and could account for their expanding functions such as eradication of obsolete proteins, antigen presentation, or "Trojan horses" for viruses or prions. The potential of dendritic cell-derived exosomes (Dex) as cell-free cancer vaccines is addressed in this review. Lessons learned from the pioneering clinical trials allowed reassessment of the priming capacities of Dex in preclinical models, optimizing clinical protocols, and delineating novel, biological features of Dex in cancer patients.
外泌体是从多泡体向内凹陷并由不同细胞类型分泌的纳米级膜泡。它们是一项“体外”发现,但具有外泌体特征的囊泡存在于生发中心和生物流体的体内。它们的蛋白质和脂质组成独特,这可能解释了它们不断扩展的功能,如清除陈旧蛋白质、抗原呈递,或作为病毒或朊病毒的“特洛伊木马”。本综述探讨了树突状细胞衍生外泌体(Dex)作为无细胞癌症疫苗的潜力。从开创性临床试验中吸取的经验教训有助于重新评估Dex在临床前模型中的启动能力、优化临床方案,并描绘癌症患者中Dex的新生物学特征。